Survival analysis of sequential use of first-line tamoxifen versus aromatase inhibitors for estrogen-positive metastatic breast cancer in postmenopausal women

V. Kyritsis; M. de Lemos; C. Speers; J. Barnett

doi:10.1200/jco.2008.26.15_suppl.1093

Survival analysis of sequential use of first-line tamoxifen versus aromatase inhibitors for estrogen-positive metastatic breast cancer in postmenopausal women

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.1093 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 1093-1093 ◽

Cited By ~ 1

Author(s):

V. Kyritsis ◽

M. de Lemos ◽

C. Speers ◽

J. Barnett

Keyword(s):

Breast Cancer ◽

Survival Analysis ◽

Metastatic Breast Cancer ◽

Postmenopausal Women ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

First Line

Download Full-text

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.01.015 ◽

2019 ◽

Vol 19 (3) ◽

pp. e452-e458

Author(s):

Yizhao Xie ◽

Yi Li ◽

Yinbin Zhang ◽

Shuqun Zhang ◽

Wei Li ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Clinical Practice ◽

Retrospective Study ◽

Postmenopausal Women ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

Nonsteroidal Aromatase Inhibitors

Download Full-text

Implications of First-Line Adjuvant Treatment with Aromatase Inhibitors in Recurrent Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2004.s.011 ◽

2004 ◽

Vol 5 ◽

pp. S24-S30

Author(s):

Lisa E. Sokolowicz ◽

William J. Gradishar

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitors ◽

Adjuvant Treatment ◽

Metastatic Breast ◽

First Line

Download Full-text

A Randomised Trial of Sequential Aromatase Inhibitors (AI) in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer. The SAINT Trial

http://isrctn.org/> ◽

10.1186/isrctn99515843 ◽

2012 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Postmenopausal Women ◽

Aromatase Inhibitors ◽

Randomised Trial ◽

Locally Advanced ◽

Metastatic Breast

Download Full-text

Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2– Metastatic Breast Cancer:

Clinical Therapeutics ◽

10.1016/j.clinthera.2018.03.004 ◽

2018 ◽

Vol 40 (4) ◽

pp. 628-639.e3 ◽

Cited By ~ 7

Author(s):

Rajeev Ayyagari ◽

Derek Tang ◽

Oscar Patterson-Lomba ◽

Zhou Zhou ◽

Jipan Xie ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Postmenopausal Women ◽

Metastatic Breast ◽

Progression Free Survival ◽

First Line ◽

Free Survival

Download Full-text

Featured Clinical Trial: First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer

PsycEXTRA Dataset ◽

10.1037/e403762005-006 ◽

2005 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast Cancer ◽

Postmenopausal Women ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Abstract PS12-22: Maintenance therapy with everolimus plus aromatase inhibitors vs aromatase inhibitors as after first-line chemotherapy in HR+/HER2- metastatic breast cancer: Updated analyses of the phase III randomized MAIN-A trial

10.1158/1538-7445.sabcs20-ps12-22 ◽

2021 ◽

Author(s):

Valentina Guarneri ◽

Saverio Cinieri ◽

Maria Vittoria Dieci ◽

Carmelo Bengala ◽

Gabriella Mariani ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Maintenance Therapy ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Line Chemotherapy

Download Full-text

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-010-0974-0 ◽

2010 ◽

Vol 123 (1) ◽

pp. 9-24 ◽

Cited By ~ 50

Author(s):

Rob Riemsma ◽

C. A. Forbes ◽

A. Kessels ◽

K. Lykopoulos ◽

M. M. Amonkar ◽

...

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Hormone Sensitive ◽

First Line Treatment

Download Full-text

Progression free survival (PFS) benefit from first line endocrine based therapies in postmenopausal women with HR+ HER2- metastatic breast cancer (MBC) according to different prognostic subgroups: A combined analysis of data from PALOMA 2, MONALEESA 2, MONARCH 3, FALCON, SWOG and FACT trials

Annals of Oncology ◽

10.1093/annonc/mdy272.330 ◽

2018 ◽

Vol 29 ◽

pp. viii111

Author(s):

V. Rossi ◽

D. Giannarelli ◽

P. Berchialla ◽

C. Nisticò ◽

G. Ferretti ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Postmenopausal Women ◽

Metastatic Breast ◽

Progression Free Survival ◽

First Line ◽

Free Survival ◽

Combined Analysis

Download Full-text

Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study

Annals of Oncology ◽

10.1093/annonc/mdx365.028 ◽

2017 ◽

Vol 28 ◽

pp. v86

Author(s):

E. Jacquet ◽

A. Lardy-Cleaud ◽

B. Pistilli ◽

P. Cottu ◽

S. Delaloge ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Observational Study ◽

Endocrine Therapy ◽

Aromatase Inhibitors ◽

Metastatic Breast ◽

First Line

Download Full-text